Radiologic response rate of chemotherapy with radiotherapy in previously inoperable head and neck tumors

Radiologic response rate of chemoradiotherapy in inoperable head and neck squamous cell carcinoma; weekly versus triweekly cisplatin schedule

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016041125211N1

Enrollment

Registered

2016-04-11

Start date

2014-08-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Head and neck tumor. Condition 2: Head and neck tumor. Condition 3: Head and neck tumor. Condition 4: Head and neck tumor. Condition 5: Head and neck tumor. Condition 6: Head and neck tumor. Condition 7: Head and neck tumor. Condition 8: Head and neck tumor. Condition 9: Head and neck tumor. Condition 10: Head and neck tumor. Condition 11: Head and neck tumor. Condition 12: Head and neck tumor. Malignant neoplasm of oropharynx Malignant neoplasm of palate Malignant neoplasm of fl

Interventions

Intervention 1: In the first group IV Cisplatin will be administered with the dose of 40 mg/ m2 once weekly concurrently with radiotherapy. Intervention 2: In the second group IV Cisplatin will be adm

Treatment - Drugs

In the first group IV Cisplatin will be administered with the dose of 40 mg/ m2 once weekly concurrently with radiotherapy

In the second group IV Cisplatin will be administered triweekly with the dose of 100 mg/m2 concurrently with radiotherapy

Eligibility

Sex/Gender

All

Age

23 Years to 75 Years

Inclusion criteria

Inclusion criteria: (Inclusion criteria: Pathologic report of Squamous.cell.carcinoma ; Age 18- 70 years ; ECOG performance status of 0-1; No distant metastasis; WBC equal to more than 4000; PLT equal to more than 100000; Hb equal to more than 10; Serum Cr less than 1.5 ; Serum aminotransferase less than twice of normal range.) (Exclusion criteria: Sever medical or psychiatric disorder; Patient who dose not have a good fallow up.)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Radiologic respons rate. Timepoint: Before start of treatment and after 8-10 week of radiotherapy. Method of measurement: CTscan.	—

Secondary

Measure	Time frame
Stage of disease. Timepoint: Start of treatment. Method of measurement: TNM system.;Tumor differentiation. Timepoint: Start of treatment. Method of measurement: Patologic report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hojatoalah Shahbazian

Ahvaz, Golestan Hospital,Radiotherapy Ward

hjshahbazian@yahoo.com maedehbarahman@gmail.com+966 13 374 3057

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026